Regulation & governance

FDA Puts Alzheimer’s Prevention on the Trial Agenda
The FDA has launched a cross-centre neuroscience initiative whose first focus is Alzheimer’s prevention. It will examine whom prevention trials should enroll, what outcomes they should measure and what evidence can support a prevention claim.

Energy drinks went mainstream before their cardiac safety evidence did

HRR Testing Moves Upfront in Prostate Cancer

Europe Has Plans. Implementation Is Lagging

FDA Redraws the TMB-High Treatment Line

Ebola’s Vaccine Trial Enters New Territory

ESCAT v2 Makes Resistance Clinically Actionable

Endometrial Cancer Gets a Strong ADC Win

One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.

The Mystery Patient Found The Gaps
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
